FSHD Global Announces Funding for miRecule 2nd generation therapy
FSHD Global Research Foundation in Sydney is excited to announce it has invested in miRecule’s second generation drug development program
Stay connected with the latest developments in FSHD research and community progress. This is your trusted hub for updates on scientific breakthroughs, inspiring personal stories, and the work we’re doing globally to accelerate treatments and a cure for Facioscapulohumeral Muscular Dystrophy (FSHD).
By staying informed and engaged, you’re helping us raise awareness, support individuals and families impacted by FSHD, and drive real momentum toward lasting solutions.
FSHD Global Research Foundation in Sydney is excited to announce it has invested in miRecule’s second generation drug development program
FSHD Global’s own Emma Weatherley was featured on an episode of Radio National Breakfast where she shared her personal story
SEOUL, South Korea, July 06, 2026 (GLOBE NEWSWIRE) — NovMetaPharma Co., Ltd. (“NovMetaPharma” or “NMP”), a clinical-stage biopharmaceutical company that
Epicrispr trial using Springbok AI twin shows positive clinical evidence of increased lean muscle, including results from an Australian site

This method improves sensitivity and helps broaden the definition of genetic FSHD to more accurately correspond to clinical FSHD, allowing identification of those at risk in affected families and in large population studies.
Encouraging news from the Avidity/Novartis trial using targeted siRNA to suppress DUX4 in FSHD. The therapy, del-brax, is an investigational
We publish a monthly newsletter to keep the FSHD community informed, connected, and inspired. If there’s a story you’d like to tell, a question you’d like answered, or a topic you think we should explore, we’d love to hear from you.
Send an email to admin@fshdglobal.org.